CAY10603

For research use only. Not for use in humans.

目录号:S7596 别名: BML-281

CAY10603 Chemical Structure

CAS No. 1045792-66-2

CAY10603 (BML-281)是一种强效的选择性HDAC6抑制剂,IC50为2 pM,选择性比其它HDACs高200多倍。

规格 价格 库存 购买数量  
RMB 1181.73 现货
RMB 3898.21 现货
RMB 8177.36 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的CAY10603发表文献15篇:

客户使用该产品的4个实验数据:

  • U87 and U251 cells were treated with HDAC6 selective inhibitors and the cells were harvested for subsequent western blot analysis.

    Cancer Lett, 2016, 379(1):134-42. CAY10603 purchased from Selleck.

  • HPAECs were pre-treated with CAY10603 (CAY, 0.1 μM) for 6 h, then challenged with TNFα (20 ng/ml) for 18 h. Cells were divided into 4 groups: Control (Con), TNF-α alone (TNFα), CAY10603 alone (CAY), and TNF-α+CAY10603 (TNFα+CAY). Representative blots and densitometry analysis of cleaved caspase-3. *P < 0.05 versus TNF-α group, n = 3.

    Oncotarget, 2016, 7(34):54714-54722. CAY10603 purchased from Selleck.

  • (C) Western blot analysis of a panel of anti-apoptotic and pro-apoptotic proteins in samples treated with different doses of CAY10603.

    Oncol Rep, 2016, 36(1):589-97. CAY10603 purchased from Selleck.

  • Effect of HDAC6 inhibitors on EGFR signaling and sorafenib-mediated EGFR stabilization and activation. a, b A549 and H460 cells were treated with different doses of CAY10603 (a) or ACY1215 (b) for 48 h and then phosphorylated, and total protein levels were evaluated by western blotting. c, d H460 cells were treated with 0.5 μM sorafenib alone or in combination with 0.05 μM CAY10603 (c) or 1 μM ACY1215 (d) for 48 h and then phosphorylated, and total protein levels were evaluated by western blotting.

    Med Oncol, 2016, 33(5):50.. CAY10603 purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 CAY10603 (BML-281)是一种强效的选择性HDAC6抑制剂,IC50为2 pM,选择性比其它HDACs高200多倍。
靶点
HDAC6 [1]
(Cell-free assay)
2 pM
体外研究

CAY10603,通过抑制HDAC6,对胰腺癌细胞系表现出有效的抗增殖活性,IC50 <1 μM,其可以用作新的分子探针以探索HDAC的生物学性能。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Panc04.03 cells NF34dm1Rem:uaX\ldoF1cW:wIHHzd4F6 M{XGeVczKGh? NIXLb5ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDhcoMxPC5yMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOSEQvF2= M4jqe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkSyPFkzLz5zOE[0Nlg6OjxxYU6=
human MiaPaca2 cells Mn23VJJwdGmoZYLheIlwdiCjc4PhfS=> NFLabHg4OiCq M1zYbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXnhVIFk[TJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEh|ryP M2TDXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkSyPFkzLz5zOE[0Nlg6OjxxYU6=
human HupT3 cells NXnOc3RmWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUm3NkBp M2X0b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXwWFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkOg{txO MlHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NEK4PVIoRjF6NkSyPFkzRC:jPh?=
HPDE 6c7 cells MVjDfZRwfG:6aXPpeJkh[XO|YYm= MnfnO|IhcA>? NHXSbFNEgXSxdH;4bYNqfHliYXfhbY5{fCCKUFTFJFZkPyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOUDPxE1? NWLVbGZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OFI5QTJpPkG4OlQzQDl{PD;hQi=>
human SU.86.86 cells MkLxVJJwdGmoZYLheIlwdiCjc4PhfS=> Ml;UO|IhcA>? MljURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVT64Ok45PiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOkDPxE1? NW\kUGxoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OFI5QTJpPkG4OlQzQDl{PD;hQi=>
human BxPC3 cells NGTwXWJRem:uaX\ldoF1cW:wIHHzd4F6 Mn3rO|IhcA>? NWrPV|V{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCfHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGg{txO MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ2Mki5Nkc,OTh4NEK4PVI9N2F-
HMEC MWHDfZRwfG:6aXPpeJkh[XO|YYm= MkC0O|IhcA>? MnTiR5l1d3SxeHnjbZR6KGGpYXnud5QhUE2HQzDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTFizszN MoXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NEK4PVIoRjF6NkSyPFkzRC:jPh?=
sf9 MYPGeY5kfGmxbjDhd5NigQ>? MkXjOUB1dyBzMDDtbY5{ MYnJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhUGm|L1\MRWchfGGpZ3XkJIh2dWGwIFjERWMyKChzIITvJFQ5OiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDpcpNm[3RiY3XscJMhfXOrbnegdFU{KCh|N{mgeI8hOzh{IILld4llfWW|KTDk[ZJqfmWmIH\seY9zd2enbnnjJJBmeHSrZHWgVmhMU0GlIHHzJJN2[nO2cnH0[UBxemWrbnP1ZoF1\WRiZn;yJFUhfG9iMUCgcYlveyxiSVO1NF0xNjByM{NOwG0v MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTRzNEiwNUc,OzF2MUS4NFE9N2F-
sf9 M2HTZWZ2dmO2aX;uJIF{e2G7 MnzmOUB1dyBzMDDtbY5{ MYLJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IF6teIVzdWmwYXygS3NVNXSjZ3fl[EBpfW2jbjDISGFEPiBqMTD0c{AyOjF3IILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JIlve2WldDDj[YxteyC3c3nu[{BxPTNiKEO3PUB1dyB|OEKgdoV{cWS3ZYOpJIRmemm4ZXSg[ox2d3KxZ3XubYMheGWydHnk[UBTUEuNQXOgZZMhe3Wkc4TyZZRmKHC{ZXnuZ5Vj[XSnZDDmc5IhPSC2bzCxNEBucW6|LDDJR|UxRTBwMEGzPO69VS5? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTRzNEiwNUc,OzF2MUS4NFE9N2F-
HeLa NU\NblFKTnWwY4Tpc44h[XO|YYm= MoHaNkBpenN? M{CzN2lvcGmkaYTpc44hd2ZiZInlMYxi[mWuZXSgeJJi[2W{IHLpcoRqdmdidH:gTGRCSzFyIDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hcHWvYX6gTIVN[SClZXzsd{Bu\WG|dYLl[EBi\nSncjCyJIhzeyCkeTDuZY5wNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[U1j[XOnZDDCVmVVKGG|c3H5MEBKSzVyPUCuO|k1OzQQvF2u NWnhdoJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5OlQzQTBpPkOwPVY1OjlyPD;hQi=>
TC32 Ml7IdWhVWyCjc4PhfS=> NFnU[3hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= Mny0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY MWTxTHRUKGG|c3H5 MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NH[zVog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 MV7xTHRUKGG|c3H5 NIfzNo1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NGjq[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MWPxTHRUKGG|c3H5 M{j6OJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MmTldWhVWyCjc4PhfS=> MoG2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M{fNNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 MUfxTHRUKGG|c3H5 MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? Mon0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 M{j5VZFJXFNiYYPzZZk> NX\MfG1GeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> NGPFcoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
U-2 OS NGXhN5ByUFSVIHHzd4F6 MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| M1zpdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NUnMeXJCeUiWUzDhd5NigQ>? NVnwSGNxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MWXxTHRUKGG|c3H5 MmXmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MmTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MmPmdWhVWyCjc4PhfS=> NHXlW2xyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 MorudWhVWyCjc4PhfS=> NHHGcJNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= M3zpV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 MX;xTHRUKGG|c3H5 NHvS[m9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NXLndIJQeUiWUzDhd5NigQ>? M2fzSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MnWzdWhVWyCjc4PhfS=> NE\qTXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz M2PmW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NFLJTI9yUFSVIHHzd4F6 NVy5b5pneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 MWrxTHRUKGG|c3H5 MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NHLq[Hg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 M{DLRZFJXFNiYYPzZZk> M4rBTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MnPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MlXJdWhVWyCjc4PhfS=> Mor3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR|IHPlcIx{ NU\3TW4zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NHn4XGVyUFSVIHHzd4F6 M4LtcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq NEfYdWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NWLKbIhleUiWUzDhd5NigQ>? NIfxXmxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NUDHN5hORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 MWPxTHRUKGG|c3H5 M2\FZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{ M3vsNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 M2\XcpFJXFNiYYPzZZk> M3XTbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? NVfEeHE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS Ml;zdWhVWyCjc4PhfS=> M4XCOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>? Mn;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 M{OycJFJXFNiYYPzZZk> MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz NHjU[Is9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MlvUdWhVWyCjc4PhfS=> NX2wTWdzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM> NGHHboY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 MVjxTHRUKGG|c3H5 NV;Vd5lOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NUnLcWpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 Ml7pdWhVWyCjc4PhfS=> M1;WUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> NYWwNYJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NYTVdog5eUiWUzDhd5NigQ>? NI\4XIZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MV4-11 MVfGeY5kfGmxbjDhd5NigQ>? MUixJIhz NXLiPIl7SmmwZHnu[{Bi\m[rbnn0fUB1dyCKRFHDOkBqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2WubIXsZZIheHKxdHXpckB{fGGkaXzpfoF1cW:wIHH0JFEhfUxicILlbY5kfWKjdHXkJIZweiBzIHjyJIZwdGyxd3XkJIJ6KGinYYTpcoch[XRiNUKg[IVoemWnIFOg[o9zKDNwNTDtbY5{KGK7IFPFWHNC NUDKfowzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{KyNVI4OzBpPkOyNlEzPzNyPD;hQi=>

... Click to View More Cell Line Experimental Data

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

HDAC 抑制试验:

纯化的HDACs与1 mM羧基荧光素(FAM)-标记的乙酰化多肽底物和测试化合物在HDAC试验缓冲液中于25℃下培养17小时,试验缓冲液包含100 mM HEPES (pH 7.5),25 mM KCl,0.1% BSA,和0.01% Triton X-100。加入包含0.078% SDS的缓冲液(终SDS浓度为0.05%)终止反应。底物和产物使用Caliper LabChip 3000系统电泳分离,以蓝色激光激发,绿色荧光检测(CCD2)。底物和产品峰的荧光强度使用Well Analyzer软件在Caliper系统中检测。对每个样品,反应重复进行两次。IC50值使用Microsoft Excel 中IDBS XLFit版4.2.1 插件和XLFit 4参数Logistic模型: ((A+((B_A)/1+((C/x)D))))自动计算,公式中X是化合物浓度,A和B分别为估计的最小和最大抑制百分比,C是拐点,D是S形曲线的Hill斜率。IC50的标准差使用Microsoft Excel 中IDBS XLFit版4.2.1 插件和公式xf4_FitResultStdError自动计算。
细胞实验:[1]
- 合并
  • Cell lines: BxPc-3,HupT3,Mia Paca-2,Panc 04.03,和 SU 86.86 细胞
  • Concentrations: ~50 μM
  • Incubation Time: 72小时
  • Method: 胰腺癌细胞系BxPc-3,HupT3,Mia Paca-2,Panc 04.03,和SU 86.86在包含10%胎牛血清和左旋谷酰胺的培养基(DMEM或RPMI)中生长。胰腺癌细胞重复两份接种在96孔板的6孔中。接种4小时后,各孔用稀释剂(DMSO)或不同浓度的SAHA或指示的1 nM到50 mM浓度的HDACIs进行处理。细胞毒性在处理后 “0”,和 72 小时使用比色MTT法根据制造商的建议进行测量。IC50值使用XLfit计算。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 89 mg/mL (199.32 mM)
Water Insoluble
Ethanol '5 mg/mL warmed
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+50% PEG 300+ddH2O
9mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 446.5
化学式

C22H30N4O6

CAS号 1045792-66-2
储存条件 粉状
溶于溶剂
别名 BML-281

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use CAY10603 and Tubastatin A via IP for mice. What can serve as the working solution instead of DMSO?

  • 回答:

    S7596 CAY10603 can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 9mg/ml as a clear solution. The dissolving protocol is the same as S8049.

免费分装抑制剂

HDAC Signaling Pathway Map

相关HDAC产品

Tags: 购买CAY10603 | CAY10603供应商 | 采购CAY10603 | CAY10603价格 | CAY10603生产 | 订购CAY10603 | CAY10603代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID